Gene therapy side effects prompt search for new delivery methods
SAN FRANCISCO — Just a few years since the first gene therapies became available, there has been a shift among small biotechs and large pharma companies about how to best deliver the edited genes, in particular regarding the viruses and other vectors that insert gene therapy payloads into cells.
The goal of these new delivery techniques is a more precise mechanism less likely to produce harmful side effects, and the shift is likely to ripple through the sector.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.